Walleye Capital LLC Ligand Pharmaceuticals Inc Call Options Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$82.7 - $110.11 $8,270 - $11,011	100 New	100 $10,000
Q4 2023 Feb 14, 2024	BUY	$49.57 - $72.63 $371,775 - $544,725	7,500 Added 576.92%	8,800 $628,000
Q3 2023 Nov 14, 2023	BUY	$58.86 - $72.67 $76,518 - $94,471	1,300 New	1,300 $77,000
Q3 2022 Nov 14, 2022	BUY	$0.01 - $107.56 $1 - $10,756	100 New	100 $9,000
Q4 2019 Feb 14, 2020	SELL	$96.94 - $113.59 $1.26 Million - $1.48 Million	-13,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$86.25 - $120.16 $319,125 - $444,592	-3,700 Reduced 22.16%	13,000 $1.29 Million
Q2 2019 Aug 14, 2019	BUY	$107.38 - $129.34 $1.79 Million - $2.16 Million	16,700 New	16,700 $1.91 Million

256

18.1M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.84B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.